Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge

J Infect Dis. 1997 Feb;175(2):441-4. doi: 10.1093/infdis/175.2.441.

Abstract

Transgenic (Tg) mice expressing the human poliovirus receptor (PVR) were vaccinated with inactivated poliovirus vaccine (IPV) and evaluated for induced immunity against type 3 poliomyelitis. One injection of monovalent type 3 IPV elicited protective immunity against wild-type poliovirus. In contrast, 2 injections of trivalent IPV were required for protection. Neutralizing antibody response and protection were vaccine dose-dependent. Administration of polio-immune mouse plasma protected unimmunized mice, demonstrating that neutralizing antibody was sufficient for immunity. IPV heated to remove its D antigen component did not induce protection in Tg PVR mice. IPV derived from a wild-type poliovirus strain gave better protection against wild-type viral challenge than IPV derived from an attenuated poliovirus strain. The newly developed Tg PVR mouse-protection test may be useful in evaluating existing IPV potency tests and for attempts to improve formulations of trivalent IPV or combined vaccines for childhood immunization schedules.

MeSH terms

  • Animals
  • Dose-Response Relationship, Immunologic
  • Immunization, Passive
  • Membrane Proteins*
  • Mice
  • Mice, Transgenic
  • Neutralization Tests
  • Poliomyelitis / genetics*
  • Poliomyelitis / immunology
  • Poliomyelitis / prevention & control*
  • Poliovirus / immunology*
  • Poliovirus Vaccine, Inactivated / administration & dosage
  • Poliovirus Vaccine, Inactivated / immunology*
  • Receptors, Virus / genetics*
  • Vaccines, Inactivated / analysis
  • Vaccines, Inactivated / immunology

Substances

  • Membrane Proteins
  • Poliovirus Vaccine, Inactivated
  • Receptors, Virus
  • Vaccines, Inactivated
  • poliovirus receptor